Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

Core Viewpoint - YKYY018 aerosol inhalation agent developed by Yuyuan Pharmaceutical has received FDA approval for clinical trials, marking a significant step in addressing the unmet medical need for RSV infection treatment globally, as no such drug has been approved for market yet [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kexin Pharmaceutical Technology Co., Ltd., has obtained FDA approval for YKYY018 to be used in clinical trials for the prevention and treatment of RSV infection [1] - YKYY018 is an internationally original membrane fusion inhibitor drug developed through a comprehensive AI platform [1] Industry Summary - There is a significant and urgent unmet medical need in the clinical treatment field for RSV infections, as there are currently no approved drugs available globally for this indication [1]

证券代码：688658 证券简称：悦康药业 公告编号：2025-049 悦康药业集团股份有限公司 关于自愿披露子公司 YKYY018 雾化吸入剂 获得 FDA 临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、函告主要内容： 1、药品名称：YKYY018 雾化吸入剂 2、IND 编号：178457 3、申请适应症：预防和治疗呼吸道合胞病毒（RSV）感染 4、申请人：北京悦康科创医药科技股份有限公司 5、申报阶段：临床试验 6、审批结论：YKYY018 雾化吸入剂临床试验申请获得美国 FDA 批准，同 意本品按照提交的方案开展临床试验。 二、其他情况 1、关于呼吸道合胞病毒 RSV 呼吸道合胞病毒（RSV）是一种普遍存在且具有传染性的有包膜的 RNA 病 毒，可引起呼吸道疾病，尤其易感染儿童、老年人及免疫功能受损人群等易感 悦康药业集团股份有限公司（以下简称"公司"）全资子公司北京悦康科创 医药科技股份有限公司（以下简称"悦康科创"）于近日获得美国食品药品监督 管理局（以下简称"FDA"）关于同意 YK ...

Core Viewpoint - Yuyuan Pharmaceutical's subsidiary has received FDA approval for clinical trials of YKYY018, a novel aerosol inhalation drug aimed at preventing and treating respiratory syncytial virus (RSV) infections, addressing a significant unmet medical need in the market [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kecai Pharmaceutical Technology Co., Ltd., has developed YKYY018, an original membrane fusion inhibitor drug utilizing a full-process AI platform [1] - The drug is positioned to fill a gap in the market as there are currently no approved treatments for RSV infections globally [1] Industry Summary - The clinical treatment field for RSV infections shows a significant and urgent unmet demand, highlighting the potential market opportunity for new therapeutic options [1]

Core Insights - YKYY018 aerosol inhalation agent has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] - The product is developed by the company's subsidiary, leveraging a full-process AI platform, and is an international original membrane fusion inhibitor [1] - YKYY018 has a novel mechanism of action, specifically binding to the F protein's HR1 region of RSV, inhibiting viral fusion with host cells, thus providing both therapeutic and preventive effects [1] - The company holds core patent rights for YKYY018 and has exclusive global rights to the product [1]

Core Viewpoint - YKYY018 aerosol inhalation agent has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Group 1 - The company, Yuyuan Pharmaceutical (688658.SH), announced that its wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., has obtained a Study May Proceed Letter from the FDA [1] - The IND number for the clinical trial is 178457 [1]

Core Viewpoint - YKYY018 aerosol inhalation agent developed by the company has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Company Summary - The company’s wholly-owned subsidiary, Beijing YKANG Kechuang Pharmaceutical Technology Co., Ltd., has obtained the FDA's Study May Proceed Letter for YKYY018 [1] - YKYY018 is an internationally original membrane fusion inhibitor drug developed using the company's AI platform, specifically targeting RSV infections [1] - The product has a novel mechanism of action, binding specifically to the HR1 region of the F protein of RSV, inhibiting the formation of the 6-HB structure, and blocking the fusion process between the virus and host cells [1] - The company holds core patent rights for YKYY018 and possesses global exclusive rights to the product [1]

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials for its inhalation aerosol YKYY018, aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Group 1 - The full subsidiary of the company, Beijing YKYY Technology Co., Ltd., is responsible for the development of YKYY018 [1] - The FDA issued a "Study May Proceed Letter" with IND number 178457, indicating regulatory approval for the clinical trial [1]

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Group 1 - The Shanghai Composite Index closed at 3864.18 points, remaining above the six-month moving average, with a slight decline of -0.15% [1] - The total trading volume of A-shares reached 1,797.19 billion yuan [1] - A total of 96 A-shares have surpassed the six-month moving average, with notable stocks including Fuyuan Pharmaceutical, Meiyan Jixiang, and Yuekang Pharmaceutical, showing divergence rates of 9.66%, 9.62%, and 9.49% respectively [1] Group 2 - The top stocks with significant divergence rates include: - Fuyuan Pharmaceutical (10.00% increase, 2.37% turnover, 22.37 yuan six-month line, 24.53 yuan latest price, 9.66% divergence) - Meiyan Jixiang (10.10% increase, 2.23% turnover, 2.88 yuan six-month line, 3.16 yuan latest price, 9.62% divergence) - Yuekang Pharmaceutical (12.00% increase, 4.86% turnover, 24.55 yuan six-month line, 26.88 yuan latest price, 9.49% divergence) [1] - Other notable stocks with divergence rates include: - Yingjixin (11.93% increase, 5.68% turnover, 19.68 yuan six-month line, 21.48 yuan latest price, 9.17% divergence) - Guobai Co. (9.95% increase, 6.05% turnover, 6.60 yuan six-month line, 7.18 yuan latest price, 8.80% divergence) [1][2]